🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Rheumatologist when someone automatically calls an ANA (+) “undifferentiated connective tissue disease”

Look who made it into the news 👀🤩 Thank you EL NORTE for the interview! 🇲🇽👩🏻‍🔬 and to my mentors and colleagues! Destaca médica regia en estudio celular - Vía EL NORTE elnorte.com/destaca-medica…

Wishing the best of luck to our great research fellows, Gabriel Figueroa-Parra, MD, MSc and @Iain_Sanchez, as they return to 🇲🇽! We’re excited to see the incredible contributions you’ll make! 🌟

Muchas felicidades!! 🎉🎉🎉 Enhorabuena 👏 👨‍🎓

Care pathways among patients with SLE in the Lupus Midwest Network registry: • ~1/4 were initially seen by nephrology or dermatology • 1/4 patients had delays in access to SLE-specialized care, which were assoc. with damage • Hematologic or aPL antibodies domains, and fewer

Congratulations to Dr. Alí Duarte-García, MD, MS Alí Duarte, MD for receiving the 2024 Mary Betty Stevens, MD, Young Investigator Prize. Dr. Duarte has made important contributions to understanding the epidemiology of systemic lupus erythematosus and antiphospholipid syndrome.

We are honored to host tonight's Hess Reception, celebrating leaders in #lupusresearch. This year’s honorees are Drs. Rovin, Duarte-García, and Askanase. We’re proud to recognize their contributions to advancing lupus research. #LFAatACR #ACR24

Congratulations!!! 🤩🤩🤩🎉🎉🎉 to one of the most brilliant and hardworking colleagues and friends I’ve met.

So proud of being part of this amazing team! #ACR24

#SLE #Lupus Nepthritis #ACR24 #Rheumatology #MedTwitter

In a new summary of its 2024 Guideline for the Screening, Treatment, and Management of Lupus Nephritis, the ACR offers 41 recommendations for clinicians treating the condition. First author, Dr. Lisa Sammaritano, tells us more. #lupusnephritis

Usually everything from Eduardo Martín-Nares is quite interesting. This was not the exemption #ACR24

🚨 New Review Alert! 🚨 Dive into the evolving landscape of glucocorticoid therapy for lupus nephritis: 🔍 Historical shifts from high-dose to safer, low-dose strategies 🧬 Mechanisms, efficacy, & risks explored ⚖️ Balancing treatment efficacy with long-term safety

🚨 Breaking down the REGENCY trial 🚨 A Phase 3 RCT evaluating obinutuzumab (Obi) in lupus nephritis (LN). Let's dive into the study design, key findings, and the dosing regimens! 🧵⬇️

🔟 Final Takeaways ✅ Obi improved renal outcomes in active LN ✅ Steroid-sparing effect (more Obi pts tapered to ≤7.5 mg/day) ✅ Proteinuria reduction = better long-term kidney survival ✅ Infections (esp. COVID-19) are a key safety concern

NEW! Curious about how genetics influence autoimmune disease risk? Tune in & hear from Mehmet Hocaoglu, MD, who dives into the study of antinuclear antibody production using data from the All of Us Research Program → acr.tw/42d7QN2 ACR_Journals

Welcome Jaime! 🤩⭐️🤩⭐️

1/ 🧵The 2024 ACR Guidelines for Lupus Nephritis (LN) are here! Big shifts in screening, combo therapy, and steroid minimization. Let's break it down. Full text: acrjournals.onlinelibrary.wiley.com/doi/epdf/10.10…

Now published simultaneously in AC&R + A&R, the 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis See ACR guideline page for resources - rheumatology.org/lupus-guideline DOI link - doi.org/10.1002/acr.25… Download the article - acr.tw/44sRwJM

#ESOC2025 🏃🏻‍♀️ESCAPE MEVO sub analysis 👉🏻 prognosis by image 🧠 👉🏻EVT <12 hs not > good functional outcome 👉🏻 Good collateral status > benefit 👉🏻 ⏱️<180 min > benefit